Bookmark
Forward
QuickView for Pyridostigmine bromide (compound)
PubChem
| Name: | Pyridostigmine Bromide |
|---|---|
| PubChem Compound ID: | 4991 |
| Description: | A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. |
| Molecular formula: | C9H13N2O2+ |
| Molecular weight: | 181.212 g/mol |
| Synonyms: |
KBioSS_002083; Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl- (9CI); DivK1c_000207; NCGC00015862-01; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); NCI60_028530; 155-97-5; Lopac-P-9797; KBio2_004651; Spectrum_001603.
show more » |
DrugBank
Identification
| Name: | Pyridostigmine Bromide |
|---|---|
| Name (isomeric): | DB00545 |
| Drug Type: | small molecule |
| Description: | A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. |
| Synonyms: |
Pyridostigminum; Pyridostigmine Bromine; Pyridine N-Oxide; Pyridostigmine Bromide
|
| Brand: | Mestinon, Regonol, Mestinon-SR |
| Category: | Parasympathomimetics, Cholinesterase Inhibitors, Antimyasthenics |
| CAS number: | 155-97-5 |
Pharmacology
| Indication: | For the treatment of myasthenia gravis. |
|---|---|
| Pharmacology: |
Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier. Pyridostigmine has a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle...
show more » |
| Mechanism of Action: | Pyridostigmine inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine. |
| Absorption: | Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%. |
| Biotransformation: | Hydrolysis by cholinesterases and by liver. |
| Half Life: | 3 hours following oral administration. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
